BSLN — Basilea Pharmaceutica AG Allschwil Share Price
0.000.00%
Last trade - 00:00- CH₣521.16m
- CH₣496.36m
- CH₣208.54m
- 44
- 62
- 94
- 79
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 10.03 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -15.62% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.43 | ||
| Price to Tang. Book | 6.46 | ||
| Price to Free Cashflow | 7.18 | ||
| Price to Sales | 2.5 | ||
| EV to EBITDA | 7.88 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 28.83% | ||
| Return on Equity | 218.58% | ||
| Operating Margin | 29.34% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CH₣m | 127.63 | 148.12 | 147.76 | 157.63 | 208.54 | 215.47 | 250.83 | 9.19% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | -15.08 | +542.58 | -28.43 | +22.8 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Basilea Pharmaceutica AG Allschwil, formerly known as Basilea Pharmaceutica AG, is a Switzerland-based commercial-stage biopharmaceutical company. The Company operates in one segment, which is the discovery, development, and commercialization of pharmaceutical products to meet the needs of patients with severe bacterial and fungal infections. It launched two hospital brands, Cresemba, which is an intravenous and oral drug for the treatment of invasive fungal infections, and Zevtera, which is an intravenous antibiotic for the treatment of severe bacterial infections, especially pneumonia. Additionally, the Company has several preclinical anti-infective assets in their portfolio. Company's products are present in United States, Canada, Europe, Asia, and Africa.
Directors
- Domenico Scala CHM (56)
- David Veitch CEO (55)
- Thomas Werner VCH (64)
- Adesh Kaul CFO (46)
- Gerrit Hauck CTO (56)
- Laurenz Kellenberger CSO (53)
- Damian Heller GCN (54)
- Ursula Eberhardt OTH (58)
- Savitha Ram Moorthi OTH (55)
- Marc Engelhardt MGB (56)
- Alf Nicklasson DRC (66)
- Nicole Onetto DRC (68)
- Ronald Scott DRC (65)
- Steven Skolsky DRC (65)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- June 10th, 2002
- Public Since
- March 25th, 2004
- No. of Employees
- 164
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- SIX Swiss Exchange
- Shares in Issue
- 12,091,957
- Address
- Hegenheimermattweg 167b, ALLSCHWIL, 4123
- Web
- https://www.basilea.com/
- Phone
- +41 616061111
- Contact
- Peer Schroeder
- Auditors
- PricewaterhouseCoopers AG
Upcoming Events for BSLN
Similar to BSLN
Addex Therapeutics
SIX Swiss Exchange
BACHEM HOLDING AG
SIX Swiss Exchange
BB Biotech AG
SIX Swiss Exchange
BioVersys AG
SIX Swiss Exchange
Evolva Holding
SIX Swiss Exchange
FAQ
What is the Basilea Pharmaceutica AG Allschwil share price?
As of Today at 19:30 UTC, shares in Basilea Pharmaceutica AG Allschwil are trading at CH₣43.10. This share price information is delayed by 15 minutes.
How has the Basilea Pharmaceutica AG Allschwil share price performed this year?
Shares in Basilea Pharmaceutica AG Allschwil last closed at CH₣43.10 and the price had moved by +7.08% over the past 365 days. In terms of relative price strength the Basilea Pharmaceutica AG Allschwil share price has outperformed the FTSE Global All Cap Index by +4.4% over the past year.
What are the analyst and broker recommendations for Basilea Pharmaceutica AG Allschwil?
The overall consensus recommendation for Basilea Pharmaceutica AG Allschwil is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Basilea Pharmaceutica AG Allschwil dividend yield?
Basilea Pharmaceutica AG Allschwil does not currently pay a dividend.
Does Basilea Pharmaceutica AG Allschwil pay a dividend?
Basilea Pharmaceutica AG Allschwil does not currently pay a dividend.
When does Basilea Pharmaceutica AG Allschwil next pay dividends?
Basilea Pharmaceutica AG Allschwil does not currently pay a dividend.
How do I buy Basilea Pharmaceutica AG Allschwil shares?
To buy shares in Basilea Pharmaceutica AG Allschwil you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Basilea Pharmaceutica AG Allschwil?
As of the previous close price of CH₣43.10, shares in Basilea Pharmaceutica AG Allschwil had a market capitalisation of CH₣521.16m.
Where are Basilea Pharmaceutica AG Allschwil shares listed?
Here are the trading details for Basilea Pharmaceutica AG Allschwil:
- Country of listing: Switzerland
- Exchange: SWX
- Ticker Symbol: BSLN
What kind of share is Basilea Pharmaceutica AG Allschwil?
Based on an overall assessment of its quality, value and momentum Basilea Pharmaceutica AG Allschwil is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Basilea Pharmaceutica AG Allschwil share price forecast for 2025?
The analyst consensus target price for shares in Basilea Pharmaceutica AG Allschwil is CH₣88.54. That is 105.43% above the last closing price of CH₣43.10.
Analysts covering Basilea Pharmaceutica AG Allschwil currently have a consensus Earnings Per Share (EPS) forecast of CH₣4.01 for the next financial year.
Find out moreWhat is the trend in the Basilea Pharmaceutica AG Allschwil share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Basilea Pharmaceutica AG Allschwil. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -4.03%.
As of the last closing price of CH₣43.10, shares in Basilea Pharmaceutica AG Allschwil were trading +0.47% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Basilea Pharmaceutica AG Allschwil PE Ratio?
The Basilea Pharmaceutica AG Allschwil PE ratio based on its reported earnings over the past 12 months is 10.03. The shares last closed at CH₣43.10.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Basilea Pharmaceutica AG Allschwil?
Basilea Pharmaceutica AG Allschwil's management team is headed by:
- Domenico Scala - CHM
- David Veitch - CEO
- Thomas Werner - VCH
- Adesh Kaul - CFO
- Gerrit Hauck - CTO
- Laurenz Kellenberger - CSO
- Damian Heller - GCN
- Ursula Eberhardt - OTH
- Savitha Ram Moorthi - OTH
- Marc Engelhardt - MGB
- Alf Nicklasson - DRC
- Nicole Onetto - DRC
- Ronald Scott - DRC
- Steven Skolsky - DRC